Correction to: Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab

Correction to: Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab

Bibliographic Details
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2017-08-01
Series:	Journal of Dermatological Treatment
Online Access:	http://dx.doi.org/10.1080/09546634.2017.1307464

Similar Items

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab
by: Boni E. Elewski, et al.
Published: (2017-08-01)

The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients
by: Michael Abrouk, et al.
Published: (2017-08-01)

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
by: Paulina Maravilla-Herrera, et al.
Published: (2023-01-01)

PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis
by: A. A. Kubanov, et al.
Published: (2017-08-01)

Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients
by: Flavia Manzo Margiotta, et al.
Published: (2024-03-01)

Psoriasis: correlation between severity index (PASI) and systemic treatment
by: Maria Flavia Pereira da Silva, et al.
Published: (2013-10-01)

PASI and PQOL-12 score in psoriasis : Is there any correlation?
by: Vikas Shankar, et al.
Published: (2011-01-01)

The Relationship Between Interatrial Block and PASI Score in Patients with Psoriasis
by: Nijad Bakhshaliyev, et al.
Published: (2021-03-01)

Clinical evaluation of different therapeutic modalities in psoriasis by Pasi score
by: Neerja Puri, et al.
Published: (2013-01-01)

Importância da variação do PASI realizado por diversos observadores Inter-rater concordance study of the PASI (Psoriasis Area and Severity Index)
by: Joana Ribeiro Costa de Faria, et al.
Published: (2010-10-01)

PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis
by: Carlo Giovanni Carrera, et al.
Published: (2018-07-01)

comment: Clinical evaluation of different therapeutic modalities in psoriasis by Pasi score
by: Hisayoshi Imanishi, et al.
Published: (2013-01-01)

Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in Psoriasis Clearance
by: Albert G. Wu, et al.
Published: (2020-08-01)

Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment
by: Ali Al Raddadi, et al.
Published: (2016-01-01)

Goeckerman Regimen Reduces Alarmin Levels and PASI Score in Paediatric Patients with Psoriasis
by: Drahomíra Holmannová, et al.
Published: (2022-03-01)

Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis
by: Steven R. Feldman, et al.
Published: (2022-04-01)

Relationship of Staphylococcal Aureus Colonization with Severity of Psoriasis Vulgaris Disease According to PASI Score
by: A. Darjani, et al.
Published: (2014-01-01)

Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis
by: Gil Yosipovitch, et al.
Published: (2019-07-01)

Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life
by: Sascha Gerdes, et al.
Published: (2020-07-01)

PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines
by: Isabel Belinchón Romero, et al.
Published: (2022-04-01)

The Effects of Cardiometabolic Comorbidities on Biologic Treatment for Psoriasis with Respect to PASI Scores: A Qualitative Systematic Review
by: Osman A, et al.
Published: (2024-01-01)

Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis
by: J. M. Carrascosa, et al.
Published: (2018-02-01)

Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year
by: Najeeda Yasmeen, et al.
Published: (2022-01-01)

Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis
by: Mark Lebwohl, et al.
Published: (2022-05-01)

Pengaruh Suplementasi Vitamin D Terhadap Perubahan Skor Psoriasis Area and Severity Index (PASI) Pada Pasien Psoriasis: Studi Kasus Dengan Pendekatan Berbasis Bukti
by: Anni Rahmawati, et al.
Published: (2024-03-01)

Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders
by: Bruce Strober, et al.
Published: (2022-10-01)

Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries
by: Deepak M. W. Balak, et al.
Published: (2021-10-01)

Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy
by: J. M. Norlin, et al.
Published: (2017-08-01)

Secukinumab for plaque psoriasis
by: Gonzalo Ordenes-Cavieres, et al.
Published: (2018-11-01)

Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
by: Laura M Sawyer, et al.
Published: (2019-01-01)

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
by: Luís Puig, et al.
Published: (2019-08-01)

The Implementation of HOTS in Teaching English at Tenth Grade of MTI Pasi
by: Sesmiyanti - Sesmiyanti
Published: (2021-01-01)

Book Review: Marco Pasi. "Aleister Crowley and the Temptation of Politics."
by: Peter Staudenmaier
Published: (2014-12-01)

Pasi Väliaho. The Moving Image: Gesture and Logos circa 1900
by: Tarmo Malmberg
Published: (2008-03-01)

Comparison of Psoriasis Area and Severity Index (PASI) Scores in Patients Treated with Oral Methotrexate and A Combination of Oral Methotrexate and Narrow Band-Ultraviolet B (NB-UVB) Phototherapy
by: Ervina Rosmarwati, et al.
Published: (2022-11-01)

Secukinumab Therapy in Psoriasis Management
by: Ira Yunita, et al.
Published: (2022-03-01)

Secukinumab in generalized pustular psoriasis
by: Shraddha Madanagobalane
Published: (2018-01-01)

Identification immune response genes in psoriasis after treatment with secukinumab
by: Jing Wang, et al.
Published: (2023-04-01)

Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?
by: Natalia Kirsten, et al.
Published: (2021-10-01)

Evaluasi Program Pembinaan Atletik di Pengcab PASI Kabupaten Kuningan
by: Budi Budi, et al.
Published: (2020-07-01)